Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
7.18
-0.35 (-4.65%)
At close: Jan 9, 2026, 4:00 PM EST
7.04
-0.14 (-1.95%)
After-hours: Jan 9, 2026, 6:10 PM EST
Sight Sciences Employees
Sight Sciences had 216 employees as of December 31, 2024. The number of employees increased by 2 or 0.93% compared to the previous year.
Employees
216
Change (1Y)
2
Growth (1Y)
0.93%
Revenue / Employee
$352,093
Profits / Employee
-$213,472
Market Cap
379.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 216 | 2 | 0.93% |
| Dec 31, 2023 | 214 | -36 | -14.40% |
| Dec 31, 2022 | 250 | 38 | 17.92% |
| Dec 31, 2021 | 212 | 43 | 25.44% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGHT News
- 11 days ago - Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge - Seeking Alpha
- 2 months ago - Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewsWire
- 2 months ago - Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Sight Sciences to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 3 months ago - Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure - GlobeNewsWire
- 4 months ago - Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use - GlobeNewsWire